Results 111 to 120 of about 585,966 (213)

Receptor for activated C kinase-1 facilitates protein kinase C-dependent phosphorylation and functional modulation of GABA(A) receptors with the activation of G-protein-coupled receptors [PDF]

, 2002
GABA(A) receptors are the principal sites of fast synaptic inhibition in the brain. These receptors are hetero-pentamers that can be assembled from a number of subunit classes: alpha(1-6), beta(1-3), gamma(1-3), delta(1), epsilon, theta, and pi, but the ...
Trevor G Smart, Brandon, NJ, Jovanovic, JN, Moss, SJ, Stephen J Moss, Smart, TG, Nicholas J Brandon, Jasmina N Jovanovic   +7 more
core  

Small molecule tyrosine kinase inhibitors in pancreatic cancer

, 2008
Sachin Gupta, Bassel F El-RayesDepartment of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University, MI, USAAbstract: Pancreatic cancer has proven to be chemo-resistant, with gemcitabine being the only cytotoxic agent approved for ...
Sachin Gupta, Bassel F El-Rayes
core  

A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia

Therapeutics and Clinical Risk Management, 2015
David L Tucker, Simon A Rule Department of Haematology, Plymouth Hospitals NHS Trust, Plymouth, UK Abstract: Although chemo-immunotherapy remains at the forefront of first-line treatment for mantle cell lymphoma (MCL) and chronic lymphocytic leukemia ...
Tucker DL, Rule SA
doaj  

Protein kinase A (PKA) phosphorylation of Shp2 inhibits its phosphatase activity and modulates ligand specificity. [PDF]

, 2015
Pathological cardiac hypertrophy (an increase in cardiac mass resulting from stress-induced cardiac myocyte growth) is a major factor underlying heart failure.
O'Bryan, JP, Burmeister, BT, Wang, L, Gold, MG, Carnegie, GK, Skidgel, RA   +5 more
core  

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact

Haematologica, 2022
Jonathan J. Pinney, Sara K. Blick-Nitko, Andrea M. Baran, Derick R. Peterson, Hannah E. Whitehead, Raquel Izumi, Veerendra Munugalavadla, Karl R. Van DerMeid, Paul M. Barr, Clive S. Zent, Michael R. Elliott, Charles C. Chu   +11 more
doaj   +1 more source

Waldenström macroglobulinemia: biology, genetics, and therapy

Blood and Lymphatic Cancer: Targets and Therapy, 2016
Jonas Paludo,1,2 Stephen M Ansell,1 1Division of Hematology, 2Division of Medical Oncology, Mayo Clinic, Rochester, MN, USA Abstract: Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity characterized by the presence of a ...
Paludo J, Ansell SM
doaj  

Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia: A Single-Center Retrospective Analysis. [PDF]

Cureus
Singh M, Podder D, Jacoby AP, Saha S, Chatterji S, Ghosh S, Chattopadhyay D, Kumar J, Nag A, Javed R, Rath A, Chakraborty S, Demde R, Ghosh P, Parihar M, Zameer L, Goel G, Bhattacharya S, Majumder P, Chandy M, Nair R.   +20 more
europepmc   +1 more source

Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy. [PDF]

Res Pract Thromb Haemost
Kartika T, Buitrago L, Li J, Cunningham-Rundles C, Coller BS.   +4 more
europepmc   +1 more source

Invasive fungal infections after Bruton tyrosine kinase inhibitor treatment: a systematic review and meta-analysis. [PDF]

Blood Adv
Srisurapanont K, Meejun T, Manothummetha K, Li LX, Baddley JW, Schulz CA, Dioverti-Prono MV, Zhang SX, Avery RK, Kates OS, Permpalung N.   +10 more
europepmc   +1 more source

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL. [PDF]

Oncol Ther
Ermann DA, Stephens DM, Wang X, Varghese I, De Souza H, Sheetz C, Fu Q, Maglinte GA, Williams R, Seymour EK, van Beuge D, Shadman M, Jacobs R.   +12 more
europepmc   +1 more source